Prosecution Insights
Prosecution Insights
6 pending office actions • 2 clients • 6 examiners • 5 art units • 0 of 6 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (67%) |
| No statute on record | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIU, TRACY | 1 | 54.9% | +28.0% |
| SHIM, DAVID M. | 1 | 58.8% | +56.0% |
| NESTOR, DONNA MICHELLE | 1 | 57.5% | +43.9% |
| MOTEVALLI, OROD | 1 | — | — |
| HASTINGS, ALISON AZAR | 1 | 62.9% | +38.8% |
| WILSON, JERICA KATLYNN | 1 | 60.6% | +40.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18286944 | METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS | NESTOR, DONNA MICHELLE | 26d overdue |
| 18042748 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | HASTINGS, ALISON AZAR | 15d overdue |
| 17797368 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | WILSON, JERICA KATLYNN | 4d overdue |
| 18705079 | VALBENAZINE COMPOSITIONS | LIU, TRACY | 22d |
| 18575126 | VALBENAZINE FOR USE IN THE TREATMENT OF DYSKINESIA DUE TO CEREBRAL PALSY | SHIM, DAVID M. | 46d |
| Client (Assignee) | Pending OAs |
|---|---|
| NEUROCRINE BIOSCIENCES, INC. | 5 |
| NXERA PHARMA UK LIMITED | 1 |
| Art Unit | Apps |
|---|---|
| 1627 | 2 |
| 1614 | 1 |
| 1626 | 1 |
| 1628 | 1 |
| 1621 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18705079 | VALBENAZINE COMPOSITIONS | Neurocrine Biosciences, Inc. | LIU, TRACY | 1614 | §103 | Non-Final OA | 22d | Pending | Apr 26, 2024 |
| 18575126 | VALBENAZINE FOR USE IN THE TREATMENT OF DYSKINESIA DUE TO CEREBRAL PALSY | Neurocrine Biosciences, Inc. | SHIM, DAVID M. | 1626 | §103 | Non-Final OA | 46d | Pending | Dec 28, 2023 |
| 18286944 | METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS | Neurocrine Biosciences, Inc. | NESTOR, DONNA MICHELLE | 1627 | Other | Non-Final OA | 26d overdue | Pending | Oct 13, 2023 |
| 18280611 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR DEMENTIA | Nxera Pharma UK Limited | MOTEVALLI, OROD | 1628 | §103 | Non-Final OA | 35d overdue | Pending | Sep 06, 2023 |
| 18042748 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | Neurocrine Biosciences, Inc. | HASTINGS, ALISON AZAR | 1627 | §103 | Final Rejection | 15d overdue | Pending | Feb 23, 2023 |
| 17797368 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | Neurocrine Biosciences, Inc. | WILSON, JERICA KATLYNN | 1621 | Other | Final Rejection | 4d overdue | Pending | Aug 03, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial